Aripiprazole

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is a stub and thus not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.
Aripiprazole.png
Aripiprazole
IUPAC name: 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
Synonyms:
Formula: C23H27Cl2N3O2

 Uses: antipsychotic agent

 Properties: medication

 Hazards: see side effects & drug interactions

Mass (g/mol): CAS #:
448.38



In medicine, aripiprazole (pronunciation: ay ri pip' ray zole) is an atypical or second generation antipsychotic agent that "has both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity; structure given in first source; use associated with hyperglycemia."[1]

In the United States, the Food and Drug Administration has approved the use of aripiprazole for the treatment of schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder agitation associated with schizophrenia or mania from bipolar disorder. It is also approved as an adjunct to antidepressants.[2] The trade name is Abilify™. Although not approved for the treatment of dementia, aripiprazole has been studied in this setting.

References

  1. Anonymous (2015), Aripiprazole (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Marianna Mazza, Maria Rosaria Squillacioti1, Riccardo Daniele Pecora, Luigi Janiri1 & Pietro Bria (December 2008), "Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial", Expert Opinion on Pharmacotherapy 9 (18): 3145-3149, DOI:10.1517/14656560802504490